Adamas Pharmaceuticals Inc (ADMS) CAO Christopher B. Prentiss Sells 567 Shares
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) CAO Christopher B. Prentiss sold 567 shares of the stock in a transaction that occurred on Wednesday, March 21st. The shares were sold at an average price of $25.98, for a total transaction of $14,730.66. Following the sale, the chief accounting officer now directly owns 17,758 shares in the company, valued at $461,352.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Adamas Pharmaceuticals Inc (NASDAQ ADMS) traded down $0.32 during trading hours on Friday, hitting $24.14. 378,245 shares of the company were exchanged, compared to its average volume of 1,089,281. Adamas Pharmaceuticals Inc has a fifty-two week low of $13.50 and a fifty-two week high of $44.00. The company has a current ratio of 10.79, a quick ratio of 10.69 and a debt-to-equity ratio of 1.55. The firm has a market capitalization of $691.63, a price-to-earnings ratio of -6.06 and a beta of 1.59.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.84 million. During the same quarter last year, the firm posted ($0.68) EPS. The firm’s revenue for the quarter was up 1435.1% compared to the same quarter last year. equities analysts predict that Adamas Pharmaceuticals Inc will post -6.03 earnings per share for the current year.
A number of brokerages have issued reports on ADMS. Northland Securities began coverage on shares of Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They issued an “outperform” rating on the stock. ValuEngine raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 13th. BidaskClub raised shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. Finally, Needham & Company LLC set a $40.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, February 25th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. Adamas Pharmaceuticals has an average rating of “Buy” and an average price target of $45.14.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.